
LXR inverse agonist shows promise in liver disease
A liver-targeted LXR inverse agonist has been found to produce rapid, substantial reductions in triglycerides in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction-associated steatoticliver disease (MASLD). OrsoBio presented the results from its Phase IIa proof-of-concept study of TLC-2716 at the Endocrine Society’s Annual Meeting (ENDO 2026). Read More
